These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2137977)

  • 1. Effects of nafarelin versus danazol on lipids and calcium metabolism.
    Bergquist C
    Am J Obstet Gynecol; 1990 Feb; 162(2):589-91. PubMed ID: 2137977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nafarelin versus danazol in the treatment of endometriosis.
    Rolland R; van der Heijden PF
    Am J Obstet Gynecol; 1990 Feb; 162(2):586-8. PubMed ID: 2137976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacology of nafarelin and danazol.
    Barbieri RL
    Am J Obstet Gynecol; 1990 Feb; 162(2):581-5. PubMed ID: 2137975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.
    Fraser IS; Shearman RP; Jansen RP; Sutherland PD
    Aust N Z J Obstet Gynaecol; 1991 May; 31(2):158-63. PubMed ID: 1834049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nafarelin in the treatment of endometriosis.
    Henzl MR; Kwei L
    Am J Obstet Gynecol; 1990 Feb; 162(2):570-4. PubMed ID: 2137971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of endometriosis: a comparison of the suppressive effects of danazol and nafarelin on reproductive hormones.
    Hickok LR; Burry KA; Cohen NL; Moore DE; Dahl KD; Soules MR
    Fertil Steril; 1991 Oct; 56(4):622-7. PubMed ID: 1833245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.
    Burry KA; Patton PE; Illingworth DR
    Am J Obstet Gynecol; 1989 Jun; 160(6):1454-9; discussion 1459-61. PubMed ID: 2525337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.
    Henzl MR; Corson SL; Moghissi K; Buttram VC; Berqvist C; Jacobson J
    N Engl J Med; 1988 Feb; 318(8):485-9. PubMed ID: 2963213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis.
    Välimäki M; Nilsson CG; Roine R; Ylikorkala O
    J Clin Endocrinol Metab; 1989 Dec; 69(6):1097-103. PubMed ID: 2531153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.
    Whitehouse RW; Adams JE; Bancroft K; Vaughan-Williams CA; Elstein M
    Clin Endocrinol (Oxf); 1990 Sep; 33(3):365-73. PubMed ID: 2147597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of nafarelin acetate and danazol in the treatment of endometriosis.
    Kennedy SH; Williams IA; Brodribb J; Barlow DH; Shaw RW
    Fertil Steril; 1990 Jun; 53(6):998-1003. PubMed ID: 2140996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiendometrial antibodies in endometriosis measured by an enzyme-linked immunosorbent assay before and after treatment with danazol and nafarelin.
    Kennedy SH; Starkey PM; Sargent IL; Hicks BR; Barlow DH
    Obstet Gynecol; 1990 Jun; 75(6):914-8. PubMed ID: 2140439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.
    Ylikorkala O; Nilsson CG; Hirvonen E; Viinikka L
    Gynecol Endocrinol; 1990 Dec; 4(4):251-60. PubMed ID: 2150580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic management of endometriosis.
    Saltiel E; Garabedian-Ruffalo SM
    Clin Pharm; 1991 Jul; 10(7):518-31. PubMed ID: 1830521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET).
    Fertil Steril; 1992 Mar; 57(3):514-22. PubMed ID: 1531464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafarelin: a new medical therapy for endometriosis.
    Henzl MR; Monroe SE
    Prog Clin Biol Res; 1990; 323():343-55. PubMed ID: 2137620
    [No Abstract]   [Full Text] [Related]  

  • 17. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
    Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R
    Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
    Riis BJ; Christiansen C; Johansen JS; Jacobson J
    J Clin Endocrinol Metab; 1990 Apr; 70(4):920-4. PubMed ID: 2138631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafarelin in the management of endometriosis: quality of life assessment.
    Burry KA
    Am J Obstet Gynecol; 1992 Feb; 166(2):735-9. PubMed ID: 1531576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis.
    Letassy NA; Thompson DF; Britton ML; Suda RR
    DICP; 1990 Dec; 24(12):1204-9. PubMed ID: 2151003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.